Johnson & Johnson Adds $1 Billion in Opioid Settlement Deal
After facing an opioid crisis lawsuit last year, Johnson & Johnson added $1 billion to a $4 billion settlement deal.
According to the company, their additional contribution doesn’t mean that it admits to liability. Instead, it is the “results from continued negotiations and is intended to maximize participation in the settlement.”
After adding $1 billion, the settlement has reached a total of $5 billion.
This settlement is part of the $48 billion deal between four states and four other companies. In the larger settlement deal, the companies will give $22 billion in cash and $26 billion in other benefits, including opioid addiction treatments, data tracking, and more.
Furthermore, this settlement resolves the lawsuits that argue that the companies were a great factor in America’s opioid crisis.
“The settlement is not an admission of liability or wrongdoing, and the Company will continue to defend against any litigation that the final agreement does not resolve,” Johnson & Johnson said in a statement following the announcement of the increased settlement amount. “The settlement will provide certainty for involved parties and critical assistance for families and communities in need.”
Editor’s note on Johnson & Johnson Opioid Settlement Deal:
This piece is to inform you about Johnson & Johnson Adds $1 Billion in Opioid Settlement Deal.
If you are considered eligible to be among the class of consumers described in the article above, you may eventually be able to participate in receiving any compensation the court may award.
We’d be happy to help you take a step in the right direction, fight this issue, and better enable you to join in on any potential consumer class action. If interested, please send an email to Outreach@ConsiderTheConsumer.com, find us on Twitter or Facebook, or even connect with us directly on our website! We look forward to hearing from you all.
Similarly, please check out our current list of Class Actions and Class Action Investigations, here.
Interested in articles like these? Become a subscriber below!